Conestoga Capital Advisors, LLC on Twist Bioscience Corporation
Thesis
Twist manufactures synthetic DNA and sequencing-related products for life-science research. Improving demand across several end markets and better gross margins drove strong results and a higher sales outlook. Conestoga also sees its products benefiting from AI applications in biotechnology, which could provide a durable incremental growth engine. These trends supported a re-rating of the shares during the quarter.
“Improving gross margins and a $12 million increase to full-year revenue guidance further strengthened investor confidence”
Key risks
- Investor expectations for an AI-linked demand opportunity may exceed realizable orders.
- Following multiple expansion the stock is vulnerable to higher yields and valuation compression.
- Research spending and growth in emerging end markets remain cyclical.